Aldeyra Therapeutics, Inc. (ALDX)
0.65
+0.03
(+4.74%)
USD |
NASDAQ |
Nov 04, 16:00
0.64
-0.01
(-1.54%)
After-Hours: 20:00
Aldeyra Therapeutics Enterprise Value : -7.511M for Nov. 3, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 03, 2026 | -7.511M |
| November 02, 2026 | -9.767M |
| October 30, 2026 | -11.15M |
| October 29, 2026 | -5.189M |
| October 28, 2026 | -3.711M |
| October 27, 2026 | -6.268M |
| October 26, 2026 | -6.238M |
| October 23, 2026 | -5.756M |
| October 22, 2026 | -6.021M |
| October 21, 2026 | -4.513M |
| October 20, 2026 | -0.6526M |
| October 19, 2026 | -4.827M |
| October 16, 2026 | -2.716M |
| October 15, 2026 | -0.4717M |
| October 14, 2026 | 2.731M |
| October 13, 2026 | 9.330M |
| October 12, 2026 | 9.692M |
| October 09, 2026 | 10.33M |
| October 08, 2026 | 12.22M |
| October 07, 2026 | 12.88M |
| October 06, 2026 | 10.30M |
| October 05, 2026 | 10.77M |
| October 02, 2026 | 25.63M |
| October 01, 2026 | 32.87M |
| September 30, 2026 | 29.25M |
| Date | Value |
|---|---|
| September 29, 2026 | 34.68M |
| September 28, 2026 | 25.03M |
| September 25, 2026 | 27.74M |
| September 24, 2026 | 28.65M |
| September 23, 2026 | 36.49M |
| September 22, 2026 | 39.20M |
| September 21, 2026 | 36.49M |
| September 18, 2026 | 37.09M |
| September 17, 2026 | 38.30M |
| September 16, 2026 | 37.69M |
| September 15, 2026 | 37.69M |
| September 14, 2026 | 43.12M |
| September 11, 2026 | 35.88M |
| September 10, 2026 | 43.12M |
| September 09, 2026 | 45.54M |
| September 08, 2026 | 47.95M |
| September 04, 2026 | 44.33M |
| September 03, 2026 | 44.33M |
| September 02, 2026 | 44.93M |
| September 01, 2026 | 44.93M |
| August 31, 2026 | 44.33M |
| August 28, 2026 | 44.63M |
| August 27, 2026 | 47.95M |
| August 26, 2026 | 49.15M |
| August 25, 2026 | 48.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Prime Medicine, Inc. | 839.76M |
| Arrowhead Pharmaceuticals, Inc. | 8.177B |
| Oncolytics Biotech, Inc. | 44.94M |
| Sangamo Therapeutics, Inc. | 40.22M |
| Sarepta Therapeutics, Inc. | 2.216B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.450M |
| Total Expenses (Quarterly) | 5.450M |
| EPS Diluted (Quarterly) | -0.0904 |
| Earnings Yield | -58.91% |
| Normalized Earnings Yield | -58.91 |